Effect and safety of escitalopram in the treatment of depressive disorder in patients with myocardial infarction: A prospective study

Background: The top two contributors to the worldwide burden of disease are predicted to be ischemic heart disease (IHD) and major depression. Patients with established IHD are at risk to develop depression. Major depression is common among patients recovering from myocardial infarction (MI). As dep...

Full description

Bibliographic Details
Main Authors: Sujata Sethi, Narender Rohilla, Kuldeep Lallar
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2016-01-01
Series:Journal of Mental Health and Human Behaviour
Subjects:
Online Access:http://www.jmhhb.org/article.asp?issn=0971-8990;year=2016;volume=21;issue=1;spage=42;epage=47;aulast=Sethi
_version_ 1818513186542845952
author Sujata Sethi
Narender Rohilla
Kuldeep Lallar
author_facet Sujata Sethi
Narender Rohilla
Kuldeep Lallar
author_sort Sujata Sethi
collection DOAJ
description Background: The top two contributors to the worldwide burden of disease are predicted to be ischemic heart disease (IHD) and major depression. Patients with established IHD are at risk to develop depression. Major depression is common among patients recovering from myocardial infarction (MI). As depression can worsen the prognosis of cardiac patients, it might be possible to improve the prognosis by treating the depression with antidepressants. Aim: The index study aimed to find the prevalence of depressive disorder in adult patients with MI admitted to the cardiology unit and to examine the outcome as regards to the effect and safety of escitalopram as per the treatment regime routinely followed for the treatment of depression in such patients. Methods: One hundred consecutive patients with an established diagnosis of MI admitted to the Department of Cardiology constituted the study sample. Patients who qualified for the major depressive disorder were then treated with escitalopram. Results: The overall prevalence of depression in patients with MI is 22%. The study highlights that depression in the post-MI period is common and responds well to antidepressant treatment. Escitalopram could be an effective and safe antidepressant for the treatment of depression in patients with MI. Conclusion: The study highlights that depression in post MI period is common and escitalopram seems to be an effective and safe antidepressant for the treatment of depression in MI patients.
first_indexed 2024-12-10T23:57:40Z
format Article
id doaj.art-f8c8dc103b1049c8a3ba8e17cd298c51
institution Directory Open Access Journal
issn 0971-8990
language English
last_indexed 2024-12-10T23:57:40Z
publishDate 2016-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Journal of Mental Health and Human Behaviour
spelling doaj.art-f8c8dc103b1049c8a3ba8e17cd298c512022-12-22T01:28:34ZengWolters Kluwer Medknow PublicationsJournal of Mental Health and Human Behaviour0971-89902016-01-01211424710.4103/0971-8990.182098Effect and safety of escitalopram in the treatment of depressive disorder in patients with myocardial infarction: A prospective studySujata SethiNarender RohillaKuldeep LallarBackground: The top two contributors to the worldwide burden of disease are predicted to be ischemic heart disease (IHD) and major depression. Patients with established IHD are at risk to develop depression. Major depression is common among patients recovering from myocardial infarction (MI). As depression can worsen the prognosis of cardiac patients, it might be possible to improve the prognosis by treating the depression with antidepressants. Aim: The index study aimed to find the prevalence of depressive disorder in adult patients with MI admitted to the cardiology unit and to examine the outcome as regards to the effect and safety of escitalopram as per the treatment regime routinely followed for the treatment of depression in such patients. Methods: One hundred consecutive patients with an established diagnosis of MI admitted to the Department of Cardiology constituted the study sample. Patients who qualified for the major depressive disorder were then treated with escitalopram. Results: The overall prevalence of depression in patients with MI is 22%. The study highlights that depression in the post-MI period is common and responds well to antidepressant treatment. Escitalopram could be an effective and safe antidepressant for the treatment of depression in patients with MI. Conclusion: The study highlights that depression in post MI period is common and escitalopram seems to be an effective and safe antidepressant for the treatment of depression in MI patients.http://www.jmhhb.org/article.asp?issn=0971-8990;year=2016;volume=21;issue=1;spage=42;epage=47;aulast=SethiDepressive disorderescitaloprammyocardial infarction
spellingShingle Sujata Sethi
Narender Rohilla
Kuldeep Lallar
Effect and safety of escitalopram in the treatment of depressive disorder in patients with myocardial infarction: A prospective study
Journal of Mental Health and Human Behaviour
Depressive disorder
escitalopram
myocardial infarction
title Effect and safety of escitalopram in the treatment of depressive disorder in patients with myocardial infarction: A prospective study
title_full Effect and safety of escitalopram in the treatment of depressive disorder in patients with myocardial infarction: A prospective study
title_fullStr Effect and safety of escitalopram in the treatment of depressive disorder in patients with myocardial infarction: A prospective study
title_full_unstemmed Effect and safety of escitalopram in the treatment of depressive disorder in patients with myocardial infarction: A prospective study
title_short Effect and safety of escitalopram in the treatment of depressive disorder in patients with myocardial infarction: A prospective study
title_sort effect and safety of escitalopram in the treatment of depressive disorder in patients with myocardial infarction a prospective study
topic Depressive disorder
escitalopram
myocardial infarction
url http://www.jmhhb.org/article.asp?issn=0971-8990;year=2016;volume=21;issue=1;spage=42;epage=47;aulast=Sethi
work_keys_str_mv AT sujatasethi effectandsafetyofescitalopraminthetreatmentofdepressivedisorderinpatientswithmyocardialinfarctionaprospectivestudy
AT narenderrohilla effectandsafetyofescitalopraminthetreatmentofdepressivedisorderinpatientswithmyocardialinfarctionaprospectivestudy
AT kuldeeplallar effectandsafetyofescitalopraminthetreatmentofdepressivedisorderinpatientswithmyocardialinfarctionaprospectivestudy